2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Genitourinary
1
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
17
Neoplasm Metastasis
11
Colorectal Neoplasms
11
Neoplasms
7
Lung Neoplasms
7
Colonic Neoplasms
6
Pancreatic Neoplasms
4
Carcinoma, Renal Cell
2
Advanced Solid Tumor
2
Solid Tumors
1
Resectable Non-Small Cell Lung Cancer
1
Rectal Neoplasms
1
Kidney Neoplasms
1
Healthy Adults
1
Brain Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
aldesleukin
43
Sunitinib
42
Cyclophosphamide
30
Nivolumab
29
pembrolizumab
27
Everolimus
27
Interferon-alpha
25
Bevacizumab
23
Sorafenib
22
Interleukin-2
20
fludarabine phosphate
19
Radiotherapy
18
Ipilimumab
18
Filgrastim
18
Axitinib
18
Gene Expression Profiling
16
Peripheral Blood Stem Cell Transplantation
15
Gemcitabine
15
cabozantinib
14
Radiosurgery
13
fludarabine
11
Doxorubicin
11
Carboplatin
11
Blood Specimen Collection
11
temsirolimus
10
atezolizumab
9
Immunohistochemistry
9
Etoposide
9
Chemotherapy, Adjuvant
9
sargramostim
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Kidney Neoplasms
×
adagrasib
×
Clear all
NCT06026410
2026-04-14
FIT-001
Kura Oncology, Inc.
Phase 1
Recruiting
300 enrolled